Reagent: HLfB Cells

Catalog Number: 1300

Lot Number: 1

Release Category: C

Provided: $4 \times 10^6$ cells/vial.

Propagation Medium: DMEM (4500 mg/L glucose), 90%; fetal bovine serum, 10%.

Freeze Medium: DMEM, 70%; fetal bovine serum, 20%; DMSO, 10%.

Growth Characteristics: Split twice weekly 1:10. HLfB cells are stable and do not need to be maintained in selection medium. If growth in selection medium is desired, propagation medium containing 500 µg/ml G418 should be used. The culture flask should be changed every two weeks.

Sterility: Negative for bacteria, fungi, and mycoplasma.

Description: HLfB cells are a HeLa derivative containing stably integrated copies of fB\(^2\), a rev-deficient HIV-1 HXB2 molecular clone.

Special Characteristics: This cell line was generated by cotransfection of HeLa cells with the plasmids fB and pSV2neo. Clone HLfB produces high levels of Gag and Env proteins only in the presence of Rev, and was selected in genetin (G418). The rev gene can be introduced into HLfB by transfection with a rev plasmid\(^3\), by fusion to a rev-expressing cell line\(^3\), or by fusion to \(E.\ coli\) protoplasts containing bacterially-expressed Rev\(^1\). High levels of virus are produced after introduction of Rev. Morphology is epithelial-like.

Recommended Storage: Liquid nitrogen

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Contributor: Dr. Barbara K. Felber and Dr. George N. Pavlakis.

References:


3Felber BK, Pavlakis GN. Cell fusion and transfection of HL3Ta and HeLa-tat cell lines. *Courier* 91-01:8-10, 1991.


NOTE: Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HLfB Cells from Dr. Barbara K. Felber and Dr. George N. Pavlakis." Also include the references cited above in any publications.

Corporate requests should be directed in writing to: B.K. Felber or G.N. Pavlakis, National Cancer Institute, FCRDC, ABL-Basic Research Program, P.O. Box B/Building 539, Room 121, Frederick, Maryland 21702-1201. Phone: (301) 846-1474, FAX (301) 846-5991.

Last Updated July 02, 2018